Results 191 to 200 of about 60,557 (265)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Uplift of genetic diagnosis of rare respiratory disease using airway epithelium transcriptome analysis. [PDF]

open access: yesHum Mol Genet
Legebeke J   +10 more
europepmc   +1 more source

Cell Culture Differentiation and Proliferation Conditions Influence the In Vitro Regeneration of the Human Airway Epithelium. [PDF]

open access: yesAm J Respir Cell Mol Biol
Redman E   +16 more
europepmc   +1 more source

A Walk in the Park: Influence of Natural Co‐Exposure to Grass Pollen and Fungal Spores on Nasal Mycobiome and Cytokine Responses

open access: yesClinical &Experimental Allergy, EarlyView.
Volunteers stayed 3 h indoors and followed 1 h outdoors in a flowering meadow. Nasal mycobiome was analysed and aeroallergen content measured in nasal filters. Airborne fungal spores were quantified and fungal isolates were sequenced. Isolated fungal spores were used for stimulation of nasal epithelial cells.
Annika Eggestein   +15 more
wiley   +1 more source

FGF receptors mediate cellular senescence in the cystic fibrosis airway epithelium. [PDF]

open access: yesJCI Insight
Easter M   +12 more
europepmc   +1 more source

Polyethylene Terephthalate Micro and Nanoplastics Induce Oxidative and Endoplasmic Reticulum Stress, Compromising Intestinal Epithelial Integrity and Viability

open access: yes
Allergy, EarlyView.
Sena Ardicli   +18 more
wiley   +1 more source

Effectiveness and Predictors of House Dust Mite Subcutaneous Immunotherapy in Polysensitised Patients With Allergic Rhinitis: A Multicentre Retrospective Study

open access: yesClinical &Experimental Allergy, EarlyView.
Single‐allergen dust mite subcutaneous immunotherapy achieved 68.8% perennial symptom response rate in polysensitised allergic rhinitis patients. High mould and dust mite sIgE levels predicted poor allergen immunotherapy response, which indicated allergen‐specific sIgE levels may help guide personalised allergen immunotherapy decisions.
Zhouxian Pan   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy